Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICP-248 + rituximab
- Development stage
- Phase 1
- Lead developer
- Innocare
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (ICP-248), Intravenous (rituximab)
01
Overview
**ICP-248 + rituximab** is a combination regimen under investigation in clinical trials for mature B-cell malignancies. ICP-248 (Mesutoclax) is a novel, orally bioavailable, highly selective BCL2 inhibitor that restores apoptosis in cancer cells by antagonizing BCL2, a key anti-apoptotic protein commonly overexpressed in B-cell malignancies. Rituximab is a well-established anti-CD20 monoclonal antibody targeting the CD20 antigen expressed on B cells, resulting in B-cell depletion via antibody-dependent cellular cytotoxicity, complement activation, and direct apoptotic signaling. The combination is being tested for synergistic efficacy, deep remission rates, reduction of minimal residual disease, and favorable safety profile in diseases such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other mature B-cell neoplasms[2][3][5].
- Other names
- MesutoclaxICP-248ICP248ICP 248rituximab
02
Targets
BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on ICP-248 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICP-248 + rituximab.